Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa

Back to Jobs

SAN DIEGO , March 02, 2018 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the U.S. Food and Drug Administration ( FDA ) has approved OTIPRIO (ciprofloxacin otic suspension) 6%

Apply Now